ELISA: suitable immunofluorescence: suitable immunohistochemistry: suitable western blot: suitable
輸送温度
wet ice
特異性
Adenovirus, hexon assembly. No cross-reactivity with Para 1-3, Influenza A & B or RSV. Non reactive with HEp-2 cells.
免疫原
Hexon from adenovirus type 5.
アプリケーション
Research Category 感染症
Research Sub Category 感染症-ウイルス
ELISA: >1:5,000
Fluorescence microscopy, indirect.
Immunoblotting: unboiled samples in 1mM DTT and 2% SDS only
Immunohistochemistry
Optimal working dilutions must be determined by end user
This Anti-Adenovirus Antibody is validated for use in ELISA, IF, WB, IH for the detection of Adenovirus.
物理的形状
Format: Purified
IgG fraction (>95% pure). In PBS (0.01 M, pH 7.2) with 0.1% sodium azide
保管および安定性
Maintain at -20° in undiluted aliquots for up to 12 months after date of receipt. Avoid repeated freeze/thaw cycles.
その他情報
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
法的情報
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
免責事項
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Encoding the sodium iodide symporter (NIS) by an adenovirus (Ad) is a promising strategy to facilitate non-invasive imaging and radiotherapy of pancreatic cancer. However, insufficient levels of NIS expression in tumor cells have limited its clinical translation. To optimize Ad-based
Highly efficient and carcinoma-specific adenoviral replication restricted by the EGP-2 promoter.
W M Gommans, P M J McLaughlin, J A C Schalk, G M M Groothuis, H J Haisma, M G Rots
Journal of Controlled Release : Official Journal of the Controlled Release Society null
Oncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are required to evaluate the mechanisms of efficacy. However, due to the species selectivity of adenovirus, there is currently no single animal model that
The clinical efficacy of conditionally replicative oncolytic adenoviruses (CRAd) is still limited by the inefficient infection of the tumor mass. Since tumor growth is essentially the result of a continuous cross-talk between malignant and tumor-associated stromal cells, targeting both cell
Last advances in the treatment of pediatric tumors has led to an increase of survival rates of children affected by primitive neuroectodermal tumors, however, still a significant amount of the patients do not overcome the disease. In addition, the survivors